TickerTalks
Browse all tickers →
TickerTalks›$GPCR
GPGPCR

Structure Therapeutics Inc.

$GPCR·$3.1B·Biotechnology·Healthcare
$54.51-0.3%YTD-28.9%1Y+194.2%
Mentions · last 7 days
2026-08-08: 2 posts2026-08-09: 3 posts2026-08-10: 4 posts2026-08-11: 2 posts2026-08-12: 9 posts2026-08-13: 3 posts2026-08-14: 7 posts30+38%
Price updated 1d ago·X counts updated 1d ago
GPGPCR
$GPCRStructure Therapeutics Inc.
$54.51-0.35%30 posts+38%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $GPCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-08-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Small-molecule GLP-1 story with a fresh 10%+ owner accumulating — priced for a binary readout, not for the current P&L.

Structure Therapeutics is a $3B pre-revenue biotech built entirely around a small-molecule GLP-1 obesity pill. The most interesting recent data point is the 8/7 Form 3 filing — a new 10%+ beneficial owner just crossed the threshold, which is the accumulation signal that typically precedes a 13D/G. Meanwhile the X conversation ties it to LLY, NVO, and VKTX as the same-basket obesity plays, with retail voices calling for a run to $100 or a buyout.

What the numbers say vs what the story says:

  • Revenue is literally $0 across the last four quarters — this is priced entirely on the 2028 launch curve (analyst FY28 estimate $213M, FY30 $832M). The stock is at 89% of the way through -29% YTD drawdown.
  • Q2 EPS -$0.49 missed by -25.6%, and Q3 will burn similarly. Cash matters far more than the P&L here — the fact that debt/equity is 0.004 is the important balance-sheet number.
  • June Reuters piece flagged 'no signs of liver injury' — the key tolerability question for oral GLP-1s that killed several competitor programs.
  • Position vs 52-week range only 47.5% despite the +185% t12m — the pattern is a big prior move that has since consolidated on light volume.

What you're watching: identity of the new 10%+ holder in any follow-up 13D filing, the next Phase 3 GEMINI readouts, and Q3 print 11/5 for cash runway.

Agrees with X sentimentX is enthusiastically bullish; the fundamentals here are literally the option premium on late-stage obesity data, so 'bullish' is the correct read if you believe the readouts hit.

What to watch: 13D/G disclosure identifying the new 10%+ holder, Phase 3 GEMINI trial updates, and Q3 print 11/5 for cash runway.

On the calendar: 2026-11-05 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-08

Structure Therapeutics is being framed as a next-leg-higher obesity/GLP-1 play. Cantor and Piper Sandler both reiterated Overweight on Viking Therapeutics with GPCR named in the same peer set alongside LLY and NVO, and a Chinese small-molecule GLP-1 competitor is being cross-analyzed as validation of the space rather than a direct threat. Retail voices are more emphatic, calling for a run toward $100 or a buyout given repeated tests of overhead resistance on light volume, though the sample is thin.

Read the AI verdict + X sentiment for $GPCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GPCR.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $GPCR

Partial — Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-19.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.49$-0.39-25.6%
Q1 2026May 7, 2026$-0.35$-0.39+10.3%
Q4 2025Feb 26, 2026$-0.49$-0.35-40.0%
Q3 2025Nov 6, 2025$-0.37$-0.36-2.8%
Next earningsThu, Nov 5·consensus EPS $-0.32

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.05$14.1M
Q4 FY25$0———$0.60$-65.9M
Q3 FY25$0———$-1.11$-52.6M
Q2 FY25$0———$-1.08$-54.8M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$41.7M$41.7M – $41.7M-$1.43-$1.69 – -$1.269
FY27$56K$56K – $56K-$1.98-$2.52 – -$1.7112
FY28$213.0M$213.0M – $213.0M-$1.54-$2.33 – $1.0510
FY29$539.4M$539.4M – $539.4M-$0.29-$0.29 – -$0.295
FY30$831.6M$831.6M – $831.6M$1.07$1.07 – $1.075

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.47%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+2.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 54.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-1.515-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 4Xichen LinCHIEF SCIENTIFIC OFFICER3.9K sh—SellJul 22Llc FmrSee Remark 117.5K sh—SellJul 14Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellJun 25Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellApr 14Llc FmrSee Remark 117.5K sh—
+ 26 other (14 awards · 6 inkinds · 3 exempts · 3 conversions) in window

See when $GPCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 73
AI summary

A new 10%+ beneficial owner filed a Form 3 initial statement of ownership for GPCR (GPCR) dated 2026-08-07. The filing reports initial beneficial ownership of shares, representing approximately a 10%+ stake of outstanding shares. Form 3 is required within 10 days of crossing the 10% ownership threshold and is an administrative disclosure. This indicates significant insider or institutional accumulation and may precede further Schedule 13D/G activity.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
8-KMaterial agreementMay 78-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
424B5Prospectus supplement (offering)May 7424B5
AI summary

Structure Therapeutics amended and restated its ATM sales agreement removing the aggregate offering cap, and filed this 424B5 to increase the maximum ATM capacity to $400M aggregate gross; approximately $58.5M (3.04M ADSs) had been sold under the prior agreement, leaving approximately $341.5M remaining capacity. Major ATM upsizing to $400M total; $341.5M remaining represents substantial ongoing dilution potential.

3New insider — initial holdingsApr 233
8-KOfficer or director changeApr 158-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 168-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 10 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profigurufocus.com·6d agoThe Next Phase Of The Obesity Drug Raceyoutube.com·64d agoStructure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)seekingalpha.com·66d agoStructure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·68d agoStructure's experimental obesity pill shows no signs of liver injuryreuters.com·71d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · last 7 days

No standout posts about $GPCR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport